我们是否正在超越氨磺必利?LB-102(N-甲基氨磺必利)用于急性精神分裂症。
完整摘要 · 中文译文
精神分裂症患病率低但疾病负担高。尽管氨磺必利用于精神分裂症,但其血脑屏障穿透能力有限。LB-102(N-甲基化氨磺必利)保留了拮抗D2和5-HT7受体的能力,且受体占据时间长于氨磺必利。一项2期临床试验(NOVA)显示,LB-102对急性精神分裂症有一定疗效,但伴随不良事件,如催乳素水平升高,需进一步研究。NOVA的住院环境可能对观察到的LB-102改善有所贡献。基于NOVA,LB Pharmaceutics已将LB-102推进至3期,用于治疗精神分裂症急性加重。与NOVA一样,NOVA2的参与者将为住院患者。因此,该试验不会解决LB-102在门诊环境中是否有效的问题,这些问题需要测试。近期获批的一种治疗精神分裂症的新方法是双位点M1/M4毒蕈碱受体激动剂呫诺美林。当呫诺美林与氨磺必利比较时,其排名较低。总之,需要进一步的临床试验来确定LB-102在住院和门诊精神分裂症治疗中是否优于氨磺必利和呫诺美林。
完整摘要 · 英文原文
Schizophrenia has a low prevalence but a high health burden. Although used in schizophrenia, amisulpride has limited blood-brain barrier penetration. LB-102 (N-methylated amisulpride) maintains the ability to antagonize D2- and 5-HT7-receptors with longer receptor occupancies than amisulpride. A phase 2 clinical trial (NOVA) has showed that LB-102 has some efficacy in acute schizophrenia, but this comes with adverse events, such as increased prolactin levels, that need further investigation. The inpatient setting of NOVA may have contributed to the improvement observed with LB-102. Based on NOVA, LB Pharmaceutics have moved LB-102 into phase 3 for the treatment of acute exacerbations of schizophrenia. Like NOVA, the participants of NOVA2 will be inpatients. Consequently, this trial will not address the issue of whether LB-102 is effective in the outpatient setting, and these needs testing. A recently approved new approach to treating schizophrenia is the bitopic M1/M4 muscarinic receptor agonist xanomeline. When xanomeline was compared to amisulpride, it ranked lower. In conclusion, further clinical trials are needed to determine whether LB-102 is better than amisulpride and xanomeline in the treatment of schizophrenia in both inpatients and outpatients.